Clinical trial · Observational
Added Value of PET/CT in Lung Cancer
Added Value of 18F-FDG PET/CT in Lung Cancer
NCT06494800CI-TRIAL-00078725unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Assess the value of PET/CT in the diagnosis, staging, response evaluation, and relapse monitoring of lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| True cut needle biobsy | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- pathologically proved lung cancer patient
- description
- All the pathologically proved lung cancer patients by true cut needle biobsy are enrolled in the study. the true cute needle biobsy procedure performed by two interventional radiologists and a pathologist. TCNB was guided by the use of a 16-detector CT device after local anesthesia is done and done either by ultrasound guidance or CT guidance.
- interventionNames
- Diagnostic Test: True cut needle biobsy
Primary outcomes (4)
- measure
- Accuracy of PET CT in diagnosis of lung cancer
- timeFrame
- 1 Year
- description
- using the qualitative and quantitative measuring including the SUV max value in detection of the malignant potentiality of the pulmonary nodule or mass comparing it with the pathological result
- measure
- Value of PET CT in staging of lung cancer
- timeFrame
- 1 Year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologically proven lung cancer patients. Exclusion Criteria: * Patients with second malignancy. * Severely ill patient (patient with disturbed consciousness level, or couldn't lie during the imaging). * Uncontrolled diabetic patient with blood glucose level more than 200mg\\dl. * Pregnant women. * Patient age \<18 years.
References
Publications (4)
- BACKGROUNDArcher JM, Truong MT, Shroff GS, Godoy MCB, Marom EM. Imaging of Lung Cancer Staging. Semin Respir Crit Care Med. 2022 Dec;43(6):862-873. doi: 10.1055/s-0042-1753476. Epub 2022 Jul 10. PMID 35815631
- BACKGROUNDLaguna JC, Garcia-Pardo M, Alessi J, Barrios C, Singh N, Al-Shamsi HO, Loong H, Ferriol M, Recondo G, Mezquita L. Geographic differences in lung cancer: focus on carcinogens, genetic predisposition, and molecular epidemiology. Ther Adv Med Oncol. 2024 Mar 6;16:17588359241231260. doi: 10.1177/17588359241231260. eCollection 2024. PMID 38455708
- BACKGROUNDPanunzio A, Sartori P. Lung Cancer and Radiological Imaging. Curr Radiopharm. 2020;13(3):238-242. doi: 10.2174/1874471013666200523161849. PMID 32445458
- BACKGROUNDKandathil A, Subramaniam RM. FDG PET/CT for Primary Staging of Lung Cancer and Mesothelioma. Semin Nucl Med. 2022 Nov;52(6):650-661. doi: 10.1053/j.semnuclmed.2022.04.011. Epub 2022 Jun 20. PMID 35738910